Premium
Microbiological and HPLC analysis of miconazole in skin, serum and phase‐solubility studies
Author(s) -
Puranajoti P.,
Kasina R.,
Tenjarla S.
Publication year - 1999
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1046/j.1365-2710.1999.00251.x
Subject(s) - bioassay , chromatography , high performance liquid chromatography , miconazole , miconazole nitrate , chemistry , extraction (chemistry) , solubility , reversed phase chromatography , biology , microbiology and biotechnology , organic chemistry , antifungal , genetics
SUMMARY Objective: To develop stability‐indicating assays for miconazole. Methods: A reversed phase high‐performance liquid chromatographic assay and a bioassay were developed. Results: The HPLC and the bioassay were linear in the range of 0·5–100 and 0·64–1·56 μg/ml, respectively. The sensitivity of HPLC and bioassay were 0.5 and 0.64 μg/ml, respectively. The bioassay was less cumbersome and much faster than the HPLC assay by obviating the need for extraction from serum. Miconazole content in the phase‐solubility studies and in the serum samples was comparatively evaluated by both assay methods. There was good correlation between the two methods ( r 2 > 0·99). The drug extraction efficiency from the serum and the skin were 97·7 and 90·2%, respectively. Where necessary, the bioassay can be an alternative choice for the HPLC analysis. The within and between day variations of the HPLC assay were 3·6 and 4·9%, respectively.